Nottingham’s biotech secures £1.8M funding for groundbreaking wound healing technology


A biotech company based in Nottingham – NuVision Biotherapies has come up with a product, which helps to heal eye injuries efficiently and wants to revolutionise the treatment of other wounds. The company recently picked up £1.8 million funding. This is the fourth fundraising round secured by NuVision to date. With this round, the total funds raised by the company is now £5 million.

Investors galore

The investment came from the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund, Mercia’s EIS funds, Newable Ventures (an existing investor), and private investors. Expecting to raise a Series A investment round in 2022, the biotech company will focus on expanding sales and carry out further clinical trials.

Rob Bennett of Mercia, which has backed the company since its inception, said: “Since our initial investment in 2015, NuVision has achieved significant milestones and is now well…

Read more…